Orpheris, a subsidiary of Ashvattha, announced the FDA has agreed to a Phase 2 clinical study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of OP-101 in patients with severe COVID-19
Ashvattha Therapeutic has been selected to present at the American Association for Cancer Research (AACR) Virtual Annual Meeting II in June, 2020.
Company to develop subcutaneously administered dendrimer-based anti-VEGF therapy with selective targeting in wet AMD. Potential therapeutic may offer significant opportunities for degenerative retinal diseases such as wet AMD and diabetic retinopathy, and may reduce significant side effects associated with systemic treatment of ocular disease.